- Home
- WFRD vs AMRX Comparison
WFRD vs AMRX Comparison
Compare WFRD & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFRD
- AMRX
- Stock Information
- Founded
- WFRD 1941
- AMRX 2002
- Country
- WFRD United States
- AMRX United States
- Employees
- WFRD N/A
- AMRX N/A
- Industry
- WFRD Metal Fabrications
- AMRX Biotechnology: Pharmaceutical Preparations
- Sector
- WFRD Industrials
- AMRX Health Care
- Exchange
- WFRD Nasdaq
- AMRX Nasdaq
- Market Cap
- WFRD 3.0B
- AMRX 2.4B
- IPO Year
- WFRD N/A
- AMRX N/A
- Fundamental
- Price
- WFRD $46.68
- AMRX $7.36
- Analyst Decision
- WFRD Strong Buy
- AMRX Strong Buy
- Analyst Count
- WFRD 8
- AMRX 5
- Target Price
- WFRD $114.50
- AMRX $10.80
- AVG Volume (30 Days)
- WFRD 1.8M
- AMRX 2.0M
- Earning Date
- WFRD 04-22-2025
- AMRX 05-02-2025
- Dividend Yield
- WFRD 1.61%
- AMRX N/A
- EPS Growth
- WFRD 19.26
- AMRX N/A
- EPS
- WFRD 6.75
- AMRX N/A
- Revenue
- WFRD $5,513,000,000.00
- AMRX $2,793,957,000.00
- Revenue This Year
- WFRD N/A
- AMRX $10.49
- Revenue Next Year
- WFRD $3.27
- AMRX $7.00
- P/E Ratio
- WFRD $6.92
- AMRX N/A
- Revenue Growth
- WFRD 7.36
- AMRX 16.73
- 52 Week Low
- WFRD $36.74
- AMRX $5.18
- 52 Week High
- WFRD $135.00
- AMRX $9.48
- Technical
- Relative Strength Index (RSI)
- WFRD 45.81
- AMRX 40.90
- Support Level
- WFRD $38.06
- AMRX $6.69
- Resistance Level
- WFRD $46.76
- AMRX $7.29
- Average True Range (ATR)
- WFRD 3.92
- AMRX 0.39
- MACD
- WFRD 0.37
- AMRX -0.04
- Stochastic Oscillator
- WFRD 55.36
- AMRX 35.71
About WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.